Skip to content

US · YDESW · BIOTECHNOLOGY

YD Bio Limited Warrants (YDESW) intrinsic value and stock valuation

$0.36as of 2026-09-18 · Mkt cap 1.19M

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

YD Bio Limited Warrants DCF and intrinsic value

InvestorsCraft values YDESW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from YDESW’s statements →

YD Bio Limited Warrants Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Taipei, TP, TW ydesgroup.com

How the business is doing

Fiscal 2025–2020, USD

Revenue
$0.00
20252020
Net income
-$-2.54T
20252020
Free cash flow
-$-253.62B
20252020
Total equity
$99.8T
20252020

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2025–2020, USD
FYFYFYFYFY
Revenue$596.8B$510.4B$350.1B$0.00$0.00
Operating income-$-5.27T-$-1.46T-$-9.85B-$-2.32T-$-1.72T
Net income-$-8.31T-$-1.41T$13.6B$3.79T$8.7T
EPSd-$-124.57K-$-340.47K$193.45$407.6K$594.9K
Operating cash flow-$-6.6T-$-1.84T-$-55.66B-$-3.02T-$-688.42B
Capital expenditure-$-1.44T-$-2.91T-$-290M$0.00-$-5M
Free cash flow-$-8.04T-$-4.75T-$-55.95B-$-3.02T-$-688.42B
Total assets$13.8T$6.86T$321.2B$17.9T$118.1T
Total debt$6.76B$22.6B$47.6B$0.00$0.00
Net debt-$-6T-$-3.11T-$-39.52B-$-14.13B-$-5.4B
Total equity-$-2.86T$6.59T$23B$11.2T$109T
Cash and short-term investments$6.01T$3.13T$87.1B$14.1B$5.4B
Income statement
FYFYFYFYFY
Revenue$596.8B$510.4B$350.1B$0.00$0.00
Cost of revenue$639B$355B$196.7B$0.00$0.00
Gross profit-$-42.15B$155.4B$153.4B$0.00$0.00
Research and development expenses$1.6T$491.4B$0.00$0.00$0.00
Selling, general and administrative expenses$3.63T$1.13T$160.6B$2.32T$1.72T
Other expenses$0.00-$-493M$2.73B$0.00$0.00
Operating expenses$5.23T$1.62T$163.3B$2.32T$1.72T
Cost and expenses$5.87T$1.97T$360B$2.32T$1.72T
Interest income$80.2B$11.8B$290M$813M$764M
Interest expense$0.00$772M$2.14B$0.00$0.00
Depreciation and amortization$209.6B$104.7B$2.45B$0.00$0.00
Ebitda-$-8.1T-$-1.28T$22.2B$3.79T$8.7T
Operating income-$-5.27T-$-1.46T-$-9.85B-$-2.32T-$-1.72T
Total other income/expenses, net-$-3.04T$75.5B$27.5B$6.11T$10.4T
Income before tax-$-8.31T-$-1.39T$17.7B$3.79T$8.7T
Income tax expense-$-1.53B$25.1B$4.09B$2.09B$0.00
Net income-$-8.31T-$-1.41T$13.6B$3.79T$8.7T
Weighted average shares outstanding$66.7T$4.15T$70.1T$9.29T$14.6T
Weighted average diluted shares outstanding$66.7T$4.15T$70.1T$9.29T$14.6T
Balance sheet
FYFYFYFYFY
Cash and short-term investments$6.01T$3.13T$87.1B$14.1B$5.4B
Net receivables$712.3B$262.8B$98.4B$18.1B$0.00
Inventory$1.88T$37.3B$69.4B$0.00$0.00
Total current assets$9.67T$3.47T$271.7B$202.7B$129.6B
Property, plant and equipment, net$67.8B$88.1B$14.3B$0.00$0.00
Goodwill and intangible assets$2.61T$2.68T$0.00$0.00$0.00
Long-term investments$0.00$10.5T$10.6B$17.7T$117.9T
Total non-current assets$4.11T$3.4T$49.5B$17.7T$117.9T
Total assets$13.8T$6.86T$321.2B$17.9T$118.1T
Accounts payable$413.3B$26.7B$18B$0.00$0.00
Short-term debt$6.76B$16.9B$47.6B$0.00$0.00
Deferred revenue$30.2B$0.00$0.00$0.00$0.00
Total current liabilities$1.64T$263.1B$298.2B$5.55T$2T
Long-term debt$0.00$5.68B$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$15T$10.9B$2.2T$1.18T$7.11T
Capital lease obligations$6.76B$22.3B$13.3B$0.00$0.00
Total liabilities$16.6T$274B$298.2B$6.74T$9.11T
Common stock$7.08B$144.2B$105.2B$17.7T$115T
Retained earnings-$-10.24T-$-1.93T-$-515.48B-$-6.53T-$-6.52T
Accumulated other comprehensive income (loss)$213.9B$45.1B$47.2B$0.00$0.00
Total equity-$-2.86T$6.59T$23B$11.2T$109T
Total investments$0.00$10.5T$10.6B$17.7T$117.9T
Total debt$6.76B$22.6B$47.6B$0.00$0.00
Net debt-$-6T-$-3.11T-$-39.52B-$-14.13B-$-5.4B
Cash flow statement
FYFYFYFYFY
Net income-$-8.31T-$-1.41T$13.6B$3.79T$8.7T
Depreciation and amortization$209.6B$104.7B$2.45B$0.00$0.00
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-1.69T-$-567.81B-$-126.7B-$-697.49B$632.2B
Accounts receivable-$-358.91B-$-11.02B-$-63.86B$0.00$0.00
Inventory-$-1.84T$28.5B-$-30.57B$0.00$0.00
Accounts payable$386.4B$10.2B$5.39B-$-530.95B$531.2B
Net cash provided by operating activities-$-6.6T-$-1.84T-$-55.66B-$-3.02T-$-688.42B
Investments in property, plant and equipment-$-1.44T-$-74.91B-$-290M$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-1.44T-$-2.9T-$-290M$100.4T-$-1.15T
Common stock issued$10.7T$7.86T$53B$0.00$0.00
Common stock repurchased$0.00$0.00$0.00-$-101.55T$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.9T$7.73T$113.9B-$-97.34T$1.15T
Net change in cash$2.88T$3.05T$57B$8.73B-$-688.42B
Cash at end of period$6.01T$3.13T$87.1B$14.1B$5.4B
Operating cash flow-$-6.6T-$-1.84T-$-55.66B-$-3.02T-$-688.42B
Capital expenditure-$-1.44T-$-2.91T-$-290M$0.00-$-5M
Free cash flow-$-8.04T-$-4.75T-$-55.95B-$-3.02T-$-688.42B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About YD Bio Limited Warrants

        YD Bio Limited specializes in pioneering diagnostic and therapeutic technologies. Its offerings encompass oncology screening solutions, regenerative treatments for ophthalmology, and advancements in exosome research. Established on February 6, 2024, the firm is based in Taipei, Taiwan.

        CEO
        Ethan Shen
        Employees
        4
        Beta
        -0.13

        Explore

        Frequently asked questions

        What is the intrinsic value of YD Bio Limited Warrants (YDESW)?

        InvestorsCraft does not currently publish an intrinsic value for YDESW. How the IC value is calculated.

        Is YDESW undervalued?

        InvestorsCraft does not publish an undervaluation signal for YDESW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.